NMD Pharma is pleased to announce that it has received approval from the Dutch ethics committee and regulatory authorities to advance its development candidate, NMD670, a small molecule inhibitor of skeletal muscle specific ClC-1 ion channels, into clinical trials as a novel treatment for the symptoms of myasthenia gravis.
Read more here: